Drug Susceptibility Profile And Pathogenicity Of H7n9 Influenza Virus (Anhui1 Lineage) With R292k Substitution
Xiaonan Zhang,Zhigang Song,Jing He,Hui-Ling Yen,Jianhua Li,Zhaoqin Zhu,Di Tian,Wei Wang,Lei Xu,Wencai Guan,Yi Liu,Sen Wang,Bisheng Shi,Wanju Zhang,Boyin Qin,Jialin Cai,Yanmin Wan,Chunhua Xu,Xiaonan Ren,Haili Chen,Lu Liu,Yuqin Yang,Xiaohui Zhou,Wenjiang Zhou,Jianqing Xu,Xiaoyan Zhang,Malik Peiris,Yunwen Hu,Zhenghong Yuan
DOI: https://doi.org/10.1038/emi.2014.80
2014-01-01
Emerging Microbes & Infections
Abstract:Neuraminidase inhibitors (NAIs) are the only available licensed therapeutics against human H7N9 influenza virus infections. The emergence of NAI-resistant variants of H7N9viruses with an NA R292K mutation poses a therapeutic challenge. A comprehensive understanding of the susceptibility of these viruses to clinically available NAIs, non-NAIs and their combinations is crucial for effective treatment. In this study, by using limited serial passage and plaque purification, an R292K variant of the Anhui1 lineage was isolated from a patient with clinical evidence of resistance to oseltamivir. In vitro and cell-based assays confirmed a high level of resistance conferred by the R292K mutation to oseltamivir carboxylate and a moderate level of resistance to zanamivir and peramivir. Non-NAI antivirals, such as T-705, ribavirin and NT-300, efficiently inhibited both the variant and the wild-type in cell-based assays. A combination of NAIs and non-NAIs did not exhibit a marked synergistic effect against the R292K variant. However, the combination of two non-NAIs ( T-705 and ribavirin) exhibited significant synergism against the mutant virus. In experimentally infected mice, the variant showed delayed onset of symptoms, a reduced viral load and attenuated lethality compared with the wild-type. Our study suggested non-NAIs should be tested clinically for H7N9 patients with a sustained high viral load. Possible drug combination regimens, such as T-705 plus ribavirin, should be further tested in animal models. The pathogenicity and transmissibility of the R292K H7N9 variant should be further assessed with genetically well-characterized pairs of viruses and, most-desirably, with competitive fitness experiments.